Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance
Author: Parker, W.
Yeoman, A.
Jamison, B.
Yeung, D.
Scott, H.
Hughes, T.
Branford, S.
Citation: British Journal of Cancer, 2013; 109(6):1593-1598
Publisher: Nature Publishing Group
Issue Date: 2013
ISSN: 0007-0920
Statement of
W T Parker, A L Yeoman, B A Jamison, D T Yeung, H S Scott, T P Hughes, and S Branford
Abstract: <h4>Background</h4>BCR-ABL1 mutation analysis is recommended for chronic myeloid leukaemia patients. However, mutations may become undetectable after changing therapy, and it is unknown whether they have been eradicated.<h4>Methods</h4>We examined longitudinal data of patients with imatinib-resistant mutations, which became undetectable by Sanger sequencing to determine whether mutations could reappear, and the related circumstances.<h4>Results</h4>Identical imatinib- and nilotinib-resistant mutations reappeared following further therapy changes in five patients, and was associated with subsequent nilotinib resistance in four.<h4>Conclusion</h4>The data suggest that some BCR-ABL1 mutations may persist at undetectable levels for many years after changing therapy, and can be reselected and confer resistance to subsequent inhibitors.
Keywords: chronic myeloid leukaemia
mutation analysis
tyrosine kinase inhibitor
Rights: © 2013 Cancer Research UK. All rights reserved.
DOI: 10.1038/bjc.2013.318
Appears in Collections:Aurora harvest
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.